Compare Ascendis Pharma A/S (ASND) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Abrdn Physical Platinum Shares ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Abrdn Physical Platinum Shares ETF trades at $14.75. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| ASND | PPLT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $25.23 |
52-Week Low | $163.32 | $11.78 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
PPLT trades at $14.77, up 1.03% with a bearish technical outlook as moving averages signal selling pressure. The ETF recently completed a 10-for-1 stock split effective May 2026, maintaining the same total value per shareholder. News coverage highlights platinum's underperformance relative to gold and silver, with Seeking Alpha downgrading the ETF to 'Hold' in May 2026 after substantial gains.
The outlook remains cautious as technical indicators show bearish momentum despite neutral oscillators. Platinum's lag in the precious metals rally presents potential catch-up opportunity, but current valuation lacks clear fundamental catalysts. Key risks include commodity price volatility and dependence on industrial demand cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
